Pfizer Inc.

Day range

$29.81 – $30.32

Open

$30.28

Prev close

$30.42

Volume

29.48M

Market cap

$173.38B

Shares out

5.7B

P/E

40.02

P/S

2.72

P/B

2.04

P/FCF

15.78

ROE

5.1%

ROA

2.1%

Debt/Equity

0.74

Div yield

5.64%

As of Oct 22, 2026

• Guidance and outlookJun 18, 2026

  Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026. The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00.

• Executive leadershipJun 18, 2026

  In connection with Mr. Denton's departure, the Company announced that Cecile Guegan, the Company's Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton's successor. Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022.

• Shareholder meetingsApr 27, 2026

  The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026. Shareholders voted on the matters set forth below. The nominees for election to the Company's Board of Directors set forth in Item 1 to the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company's next Annual Meeting of Shareholders, based upon the following votes: [detailed voting results for 12 director nominees]

• Guidance and outlookDec 16, 2025

  On December 16, 2025, Pfizer Inc. issued a press release that provided its full-year 2026 guidance and revised its full-year 2025 Revenue guidance while reaffirming all other components of its full-year 2025 financial guidance.

• Debt activityNov 21, 2025

  Pfizer Inc. completed a public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2027, $1,000,000,000 aggregate principal amount of 3.875% Notes due 2027, $1,000,000,000 aggregate principal amount of 4.200% Notes due 2030, $1,250,000,000 aggregate principal amount of 4.500% Notes due 2032, $1,250,000,000 aggregate principal amount of 4.875% Notes due 2035, $500,000,000 aggregate principal amount of 5.600% Notes due 2055 and $500,000,000 aggregate principal amount of 5.700% Notes due 2065.

• MRNAModerna, Inc. Common Stock-1.25%
• MRKMerck & Co., Inc.-1.34%
• JNJJohnson & Johnson-1.42%
• LLYEli Lilly & Co.-2.54%
• NVAXNovavax Inc-2.90%
• ABBVABBVIE INC.+0.16%
• AZNAstraZeneca PLC-0.63%
• BMYBristol-Myers Squibb Co.-2.41%

Days to cover

4.4

Short interest

150.22M

Avg volume

34.03M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
  positiveThe Motley Fool· Oct 23, 2026
• Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
  neutralThe Motley Fool· Oct 23, 2026
• Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
  positiveThe Motley Fool· Oct 22, 2026
• Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
  positiveZacks Investment Research· Oct 21, 2026